≥99% PURITY GUARANTEED•THIRD-PARTY TESTED•SAME-DAY SHIPPING USA•FREE SHIPPING $200+•
Menu
≥99% Purity
Same-Day Ship
COA Included
GLP3-R - 5 mg
Popular Peptides

GLP3-R

Tri-agonist research peptide targeting GLP-1, GIP, and glucagon receptors.

$85.00
99.48% Purity Verified

Third-Party Tested by Verum Analytics

Batch: BIL-RET-01-2602Mar 7, 2026
+99% Purity
Third-Party Tested
COA Available
29 sold in the last 24 hours
Order in 0h 0min for same-day shipping
Buy More, Save More
QuantityPrice
Add 2 more for 15% off
$85.00
Albert - Chief Researcher

Albert's Verdict

GLP3-R activates all three incretin receptors simultaneously — the breadth of metabolic signaling here is unlike anything in a single-receptor agonist. This is the one I keep coming back to.

View COA

✓ In stock - Ships same day

Arrives as lyophilized (powder) form

Shipped freeze-dried for maximum stability and shelf life. See laboratory preparation guide for handling instructions.

Secure Checkout256-bit SSL
99%+ PurityThird-Party Verified
Same-Day ShippingOrder by 2PM EST
Satisfaction Guarantee

Product Description

GLP3-R is a tri-agonist research peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. The tri-receptor approach is studied in laboratory research models of metabolic signaling pathways.

Molecular Profile:

  • Classification: Triple GLP-1/GIP/Glucagon Receptor Agonist
  • Targets: GLP-1R + GIPR + GCGR
  • Mechanism: Tri-receptor incretin and glucagon receptor activation

Research Applications:

  • Tri-receptor signaling research compared with dual/mono agonists
  • Energy-expenditure pathway research models
  • Body-composition research in preclinical models
  • Hepatic lipid metabolism research models
  • Thermogenesis and adipose tissue research models
  • Metabolic-pathway research models

Quality Standards:

  • Purity: ≥99% verified by HPLC
  • Third-party tested with COA included
  • Available in 4 sizes for dose-response laboratory studies

For laboratory handling instructions, refer to the Preparation Guide.

FOR RESEARCH USE ONLY. Not for human or animal consumption.

Technical Specifications

Molecular Formula
C237H382N66O70S
Molecular Weight
5414.91 g/mol
Sequence
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-Aib-Gln-Asp-Glu-Leu-Phe-Glu-Trp-Leu-Leu-Glu-Gln-Leu-Arg-NH2

Frequently Researched Together

Commonly studied alongside in laboratory settings

Bundle total (3 items):$162.00

Research FAQ — GLP3-R

Frequently asked questions about this compound for laboratory researchers.

What is Retatrutide / GLP-3-R?+
Retatrutide is an investigational triple-agonist research peptide that interacts with GLP-1, GIP, and glucagon receptors. Published Phase 2 trial data describe metabolic and body-composition effects under controlled clinical-research conditions.
Cited: PMID 37314979, PMID 38866447
How does Retatrutide differ from Semaglutide and Tirzepatide?+
Research literature characterizes Semaglutide as a single (GLP-1) agonist, Tirzepatide as a dual (GLP-1 + GIP) agonist, and Retatrutide as a triple (GLP-1 + GIP + glucagon) agonist. Published data on the additional glucagon-receptor activity suggest differentiated metabolic effects in clinical-research populations.
Cited: PMID 37314979
What dosing has been reported in Retatrutide clinical research?+
Phase 2 publications describe weekly subcutaneous administration of 1–12 mg in trial cohorts. Researchers should reference the cited NEJM publication and their IRB-approved protocols.
Cited: PMID 37314979
How is Retatrutide stored?+
Lyophilized Retatrutide should be stored at −20 °C protected from light. Reconstituted solution is typically held at 2–8 °C and used within 28 days. Refer to the product COA and your laboratory's SOP.

Published research references

Peer-reviewed literature relevant to GLP3-R research. Linked PubMed IDs open the original source.

  1. [1]Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial — N Engl J Med (2023) · PMID 37314979
  2. [2]Retatrutide: pharmacology, clinical trials, and mechanism of action — Diabetes Obes Metab (2024) · PMID 38866447
  3. [3]Retatrutide for type 2 diabetes: Phase 2 trial outcomes — Lancet (2023) · PMID 37322535
BL
Reviewed by the BioInfinity Research Team
Content reviewed by our research and quality team — biochemistry-degreed reviewers working alongside our analytical lab partner (Janoshik Analytical). Every product page is cross-checked against the cited peer-reviewed literature and the current batch's third-party COA.
For laboratory research use only. Not for human or veterinary use. Content is informational and does not constitute medical advice.

Learn More About This Peptide

Browse All Peptide Research →Research Guides & Protocols

Research Use Only: This product is intended for laboratory research purposes only. Not for human consumption.